O Orexo AB
O
Chiusa
19.6 0.41
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
19.32
Massimo
19.76
Entrata | 41M -75M |
|---|---|
Vendite | 1.7M 5M |
EPS | -3.812 |
Margine di Profitto | -1,500 |
Dipendenti | 65 |
EBITDA | 206M -66M |
Utili prossimi | 16 lug 2026 |
|---|
Capitalizzazione di Mercato | -53M 647M |
|---|---|
Apertura precedente | 19.19 |
Chiusura precedente | 19.6 |
Orexo AB Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Orexo AB Previsione
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
